David P Kelsen MD

Oncology•New York, NY

Professor of Medicine, Cornell University-Weill Medical College

Request appointment

160 East 53rd StreetNew York, NY 10022
Book by Phone+1(507) 708-6723

Overview of Dr. Kelsen

Dr. David Kelsen is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Sloan Kettering Bergen. He received his medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 50 years. He is experienced in cholangiocarcinoma, gastrointestinal oncology, general medical oncology, and endocrine oncology. He has more than 100 publications and over 500 citings.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1976 - 1978
Temple University HospitalResidency, Internal Medicine, 1972 - 1976
Drexel University College of MedicineClass of 1972

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 2019 - 2027
NY State Medical License 1976 - 2027
PA State Medical License 1973 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
America's Top Doctors Castle Connolly, 2003-2014

Clinical Trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Start of enrollment: 1995 Oct 01
Completed
Phase 1
Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer Start of enrollment: 1996 May 01
Completed
Phase 2
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Start of enrollment: 1997 Sep 01
Unknown status
Phase 2

Publications & Presentations

PubMed

2 citations
Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.
Mengying Hu, Di-Ao Liu, Inbal Wortzel, Paul Collier, Theodore M Nelson
Cancer Cell. 2026-05-11
2 citations
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Wungki Park, Catherine A O'Connor, Joanne F Chou, Marc Hilmi, Zeynep Tarcan
Nature Medicine. 2026-05-01
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.
Wungki Park, Catherine O'Connor, Joanne Chou, Marc Hilmi, Zeynep Tarcan
Research Square. 2025-09-01

Authored Content

Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018

Press Mentions

Modified FLOT Beats FOLFOX for Advanced Gastric CancerApril 25th, 2025
Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal AdenocarcinomaFebruary 10th, 2025
Stress Response Protein Links Inflammatory Disease to Colon CancerFebruary 19th, 2021

Grant Support

Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2011
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2010
Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8461Division Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment2009
Phase II/III Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–2000

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Kansas City Preferred-Care Blue PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment